
原料药
Paroxetine Hydrochloride Hydrate
KDMF APIs
Paroxetine Hydrochloride Hydrate
韩文名称 | 파록세틴염산염수화물 |
|---|---|
分类 | 中枢神经系统药物 |
CAS No. | 61869-08-7 |
KDMF 登记号 | 20191217-209-J-318 |
生产厂商 | Mylan Laboratories Limited |
规格 | EP |
品目信息
IUPAC Name | (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine |
|---|---|
Synonyms | (−)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine |
Description | Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine. |
Certificate of Analysis | If you need more information, please contact us. |
如需规格书 · 检验成绩书等附加资料,请在咨询时一并提出。负责人确认后将回复您。(02-579-1056 · ace@acebiopharm.com)